stockportfolio.pro
Stocks / CNTA vs LEGN
CNTA vs LEGN
Centessa Pharmaceuticals plc and Legend Biotech Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Centessa Pharmaceuticals plc (CNTA) | Legend Biotech Corporation (LEGN) | |
|---|---|---|
| Market cap | $6.1B | $6.5B |
| Revenue (latest FY) | $15.00M | $1.03B |
| Net income (latest FY) | $-197.53M | $-296.80M |
| Revenue growth (5y CAGR) | — | 106.4% |
| Net margin | -1316.9% | -28.8% |
| Return on equity | -37.5% | -29.6% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CNTA — free Open LEGN — freeFrequently asked questions
Which is bigger, CNTA or LEGN?
Legend Biotech Corporation is larger by market capitalization — $6.5B versus $6.1B.
Which grows faster, CNTA or LEGN?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.